Pranlukast Hydrate

Pranlu oral suspension is indicated for asthma and allergic rhinitis symptoms.

Pranlukast selectively antagonizes leukotriene D4 (LTD4) at the cysteinyl leukotriene receptor in the human airway. It inhibits the actions of LTD4 at the CysLT1 receptor and prevents airway edema, smooth muscle contraction and enhanced secretion of thick, viscous mucus.

Child : 3.5 mg/kg bid. Max dose : 10 mg/kg/day (not exceeding 450 mg daily). Adults : Take 2 tablets (225 mg) at a time, twice a day after breakfast and dinner. The dosage may be adjusted according to your age and symptoms. Strictly follow the instructions. Use in Children & Adolescents : There was a substantial benefit of adding pranlukast to usual therapy in asthmatic children.

Concurrent use with warfarin and other anticoagulants may cause an increase in prothrombin time.

Pranlukast is contraindicated in acute asthma attacks and hepatic impairment/cirrhosis.

Headache, increased incidence of respiratory tract infection, GI disturbances, induced generalized pain, fever, myalgia and arthralgia.

Use of pranlukast is not associated with an increased risk of pregnancy loss, gestational diabetes, preeclampsia, low maternal weight, preterm delivery, low apgar scores and reduced measures of birth length in infants. Slightly decreased birth weight in infants born to pranlukast users could be attributed to maternal asthma severity/control.

Should be cautious regarding the patients with renal impairment. Possible elevations in liver enzymes can happen. Withdraw treatment in patients showing signs consistent with Churg-Strauss syndrome.

Keep below 30°C temperature, protected from light & moisture. Keep all medicines out of reach of children.